Phase 2 Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 years or older
- People who have been diagnosed with cirrhosis (scarring of the liver), either through clinical assessment or a tissue biopsy
- People who do not currently have any active liver complications (such as fluid buildup, bleeding, or confusion related to liver disease)
- People with no previous history of liver cancer (hepatocellular carcinoma)
- People whose blood tests show that their blood cell counts, liver function, and kidney function are at acceptable levels
- People with a general health and ability-to-function score of 70 or above on the Karnofsky scale, meaning they are able to care for themselves and carry out normal activities (confirm with trial site)
- People of any sex or racial/ethnic background
- People whose FIB-4 index score is above 3.25 — this is a number calculated from blood test results that indicates the level of liver scarring (confirm with trial site)
- People who show high-risk patterns in a specific type of liver cell measurement called PLSec, taken at the start of the trial (confirm with trial site)
- People who do not carry a specific gene variant called HLA-B*35:01 (confirm with trial site)
Who may not be able to join:
- People who have previously used or are currently using EGCG, a compound found in green tea supplements
- People who have had a bad reaction to green tea products in the past
- People with severe obesity, defined as a body mass index (BMI) over 40
- People who are currently drinking alcohol
- People who are unable to complete at least four weeks of the EGCG treatment or take less than 80% of the planned doses by the end of week four
- People who develop liver cancer during the course of the study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Yujin Hoshida, MD, PhD, UT Southwestern
Phone: 214-648-3111
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in Prognostic Liver Secretome signature (PLSec) score
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.